dc.contributor.author |
Malise, TTA
|
|
dc.contributor.author |
Nweke, EE
|
|
dc.contributor.author |
Takundwa, Mutsa M
|
|
dc.contributor.author |
Fru, PF
|
|
dc.contributor.author |
Thimiri Govindaraj, Deepak B
|
|
dc.date.accessioned |
2023-09-22T12:05:23Z |
|
dc.date.available |
2023-09-22T12:05:23Z |
|
dc.date.issued |
2023-05 |
|
dc.identifier.citation |
Malise, T., Nweke, E., Takundwa, M.M., Fru, P. & Thimiri Govindaraj, D.B. 2023. Treatment strategies for multiple myeloma treatment and the role of high-throughput screening for precision cancer therapy. <i>Advances in Experimental Medicine and Biology.</i> http://hdl.handle.net/10204/13086 |
en_ZA |
dc.identifier.issn |
0065-2598 |
|
dc.identifier.uri |
https://doi.org/10.1007/5584_2023_775
|
|
dc.identifier.uri |
doi: 10.1007/5584_2023_775
|
|
dc.identifier.uri |
http://hdl.handle.net/10204/13086
|
|
dc.description.abstract |
In the past few years, development of approved drug candidates has improved the disease management of multiple myeloma (MM). However, due to drug resistance, some of the patients do not respond positively, while some of the patients acquire drug resistance, thereby these patients eventually relapse. Hence, there are no other therapeutic options for multiple myeloma patients. Therefore, this necessitates a precision-based approach to multiple myeloma therapy. The use of patient's samples to test drug sensitivity to increase efficacy and reduce treatment-related toxicities is the goal of functional precision medicine. Platforms such as high-throughput-based drug repurposing technology can be used to select effective single drug and drug combinations based on the efficacy and toxicity studies within a time frame of couple of weeks. In this article, we describe the clinical and cytogenetic features of MM. We highlight the various treatment strategies and elaborate on the role of high-throughput screening platforms in a precision-based approach towards clinical treatment. |
en_US |
dc.format |
Abstract |
en_US |
dc.language.iso |
en |
en_US |
dc.relation.uri |
https://pubmed.ncbi.nlm.nih.gov/37243923/ |
en_US |
dc.relation.uri |
https://link.springer.com/chapter/10.1007/5584_2023_775 |
en_US |
dc.source |
Advances in Experimental Medicine and Biology |
en_US |
dc.subject |
Drug screening |
en_US |
dc.subject |
Drug sensitivity |
en_US |
dc.subject |
Heterogeneity |
en_US |
dc.subject |
Multiple Myeloma |
en_US |
dc.subject |
Precision medicine |
en_US |
dc.subject |
Treatment strategies |
en_US |
dc.title |
Treatment strategies for multiple myeloma treatment and the role of high-throughput screening for precision cancer therapy |
en_US |
dc.type |
Article |
en_US |
dc.description.pages |
19 |
en_US |
dc.description.note |
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG: Due to copyright restrictions, the attached PDF file only contains the abstract of the full text item. For access to the full text item, please consult the publisher's website: https://link.springer.com/chapter/10.1007/5584_2023_775 |
en_US |
dc.description.cluster |
Next Generation Health |
en_US |
dc.description.impactarea |
Synthetic Nanobiotech Biomachs |
en_US |
dc.identifier.apacitation |
Malise, T., Nweke, E., Takundwa, M. M., Fru, P., & Thimiri Govindaraj, D. B. (2023). Treatment strategies for multiple myeloma treatment and the role of high-throughput screening for precision cancer therapy. <i>Advances in Experimental Medicine and Biology</i>, http://hdl.handle.net/10204/13086 |
en_ZA |
dc.identifier.chicagocitation |
Malise, TTA, EE Nweke, Mutsa M Takundwa, PF Fru, and Deepak B Thimiri Govindaraj "Treatment strategies for multiple myeloma treatment and the role of high-throughput screening for precision cancer therapy." <i>Advances in Experimental Medicine and Biology</i> (2023) http://hdl.handle.net/10204/13086 |
en_ZA |
dc.identifier.vancouvercitation |
Malise T, Nweke E, Takundwa MM, Fru P, Thimiri Govindaraj DB. Treatment strategies for multiple myeloma treatment and the role of high-throughput screening for precision cancer therapy. Advances in Experimental Medicine and Biology. 2023; http://hdl.handle.net/10204/13086. |
en_ZA |
dc.identifier.ris |
TY - Article
AU - Malise, TTA
AU - Nweke, EE
AU - Takundwa, Mutsa M
AU - Fru, PF
AU - Thimiri Govindaraj, Deepak B
AB - In the past few years, development of approved drug candidates has improved the disease management of multiple myeloma (MM). However, due to drug resistance, some of the patients do not respond positively, while some of the patients acquire drug resistance, thereby these patients eventually relapse. Hence, there are no other therapeutic options for multiple myeloma patients. Therefore, this necessitates a precision-based approach to multiple myeloma therapy. The use of patient's samples to test drug sensitivity to increase efficacy and reduce treatment-related toxicities is the goal of functional precision medicine. Platforms such as high-throughput-based drug repurposing technology can be used to select effective single drug and drug combinations based on the efficacy and toxicity studies within a time frame of couple of weeks. In this article, we describe the clinical and cytogenetic features of MM. We highlight the various treatment strategies and elaborate on the role of high-throughput screening platforms in a precision-based approach towards clinical treatment.
DA - 2023-05
DB - ResearchSpace
DP - CSIR
J1 - Advances in Experimental Medicine and Biology
KW - Drug screening
KW - Drug sensitivity
KW - Heterogeneity
KW - Multiple Myeloma
KW - Precision medicine
KW - Treatment strategies
LK - https://researchspace.csir.co.za
PY - 2023
SM - 0065-2598
T1 - Treatment strategies for multiple myeloma treatment and the role of high-throughput screening for precision cancer therapy
TI - Treatment strategies for multiple myeloma treatment and the role of high-throughput screening for precision cancer therapy
UR - http://hdl.handle.net/10204/13086
ER -
|
en_ZA |
dc.identifier.worklist |
26789 |
en_US |